{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:30:45Z","timestamp":1777347045143,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clineuro.2020.106070","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T18:28:24Z","timestamp":1593887304000},"page":"106070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage"],"prefix":"10.1016","volume":"195","author":[{"given":"Amarilis","family":"Giovino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Shomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten V.","family":"Busey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Case","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Brockhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Concha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clineuro.2020.106070_bib0005","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.clineuro.2020.106070_bib0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.clineuro.2020.106070_bib0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.clineuro.2020.106070_bib0020","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clineuro.2020.106070_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.clineuro.2020.106070_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.clineuro.2020.106070_bib0035","article-title":"Real-world utilization of andexanet alfa","author":"Brown","year":"2019","journal-title":"Am. J. Emerg. Med."},{"issue":"1","key":"10.1016\/j.clineuro.2020.106070_bib0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2020.106070_bib0045","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clineuro.2020.106070_bib0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor xa inhibitor-related intracranial hemorrhage (FiX-ICH): results from a multicenter, observational cohort receiving prothrombin complex concentrates","author":"Panos","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.clineuro.2020.106070_bib0055","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clineuro.2020.106070_bib0060","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1212\/01.wnl.0000261906.93238.72","article-title":"Early care limitations independently predict mortality after intracerebral hemorrhage","volume":"68","author":"Zahuranec","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clineuro.2020.106070_bib0065","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol."},{"issue":"Supplement 1","key":"10.1016\/j.clineuro.2020.106070_bib0070","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0735-1097(20)32836-9","article-title":"Real-world management of oral factor xa inhibitor bleeding-related hospitalizations with andexanet alfa or 4 factor prothrombin complex concentrate","volume":"11","author":"Coleman","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.clineuro.2020.106070_bib0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clineuro.2020.106070_bib0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajem.2017.08.042","article-title":"Management of factor xa inhibitor-associated life-threatening major hemorrhage: a retrospective multi-center analysis","volume":"36","author":"Milling","year":"2018","journal-title":"Am. J. Emerg. Med."},{"issue":"11","key":"10.1016\/j.clineuro.2020.106070_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(20)32869-2","article-title":"30 day mortality following andexanet alfa in annexa-4 compared with prothrombin complex concentrate (pcc) therapy in the orange study for life threatening non-vitamin k oral anticoagulant (noac) related bleeding","volume":"75","author":"Cohen","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.clineuro.2020.106070_bib0090","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/STROKEAHA.108.520668","article-title":"Hematoma growth in oral anticoagulant related intracerebral hemorrhage","volume":"39","author":"Cucchiara","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.clineuro.2020.106070_bib0095","first-page":"S1","article-title":"Clinical factors associated with achievement of hemostatic efficacy in patients with intracranial hemorrhage: an AnNEXA-4 substudy","volume":"31","author":"Concha","year":"2019","journal-title":"Neurocrit. Care"},{"issue":"25","key":"10.1016\/j.clineuro.2020.106070_bib0100","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846720304133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846720304133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:36:14Z","timestamp":1759588574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846720304133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"alternative-id":["S0303846720304133"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2020.106070","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2020.106070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106070"}}